BMI, tobacco, and alcohol: Roles in glaucoma progression examined in study

News
Article

The primary findings were that a higher BMI was protective against glaucoma progression and use of tobacco and alcohol were not significantly associated with retinal nerve fiber layer change.

Man holding cigarette and whiskey glass at table Image credit: AdobeStock/Parkin

Image credit: AdobeStock/Parkin

A newly published study1 found that use of tobacco and alcohol did not significantly affect the rate of change of the retinal nerve fiber layer (RNFL), while a high body mass index (BMI) was associated with slower structural changes in the visual fields, according to Asmaa A. Youssif, MD, from the Duke Eye Center, Duke University, Durham, NC, and the Department of Ophthalmology, Assiut University Faculty of Medicine, Assiut, Egypt.

Youssif and colleagues explained that while studies of obesity and tobacco and alcohol consumption showed that many chronic diseases are affected by the factors being studied, none had mentioned an effect on glaucoma progression.

In light of that gap in the medical literature, the researchers set out to determine how the RNFL fared over time in patients with glaucoma in association with the BMI and tobacco and alcohol use.

A total of 2,839 eyes (1,584 patients) with glaucoma from the Duke Ophthalmic Registry were included. All patients had undergone at least 2 spectral-domain optical coherency tomography (SD-OCT) tests over a minimum 6-month follow-up.

Information about alcohol and tobacco use was obtained from electronic health records and the mean BMI was calculated.

The authors reported that the mean follow-up time was 4.7±2.1 years and each eye had undergone a mean of 5.1±2.2 SD-OCT tests. A history of tobacco or alcohol consumption was reported by 43% and 54% of patients, respectively, and 34% of patients were obese.

The primary findings were that a higher BMI was protective against glaucoma progression (0.014 µm/year slower per each 1 kg/m2 higher; p=0.011), and use of tobacco and alcohol were not significantly associated with RNFL change rates (p=0.473 and p=0.471, respectively). Patients who were had significantly faster rates of structural loss (−0.768 µm/year; p=0.002) compared with those who had a normal weight.

Reference:
  1. Youssif AA, Onyekaba N-A, Naithani R, et al. Social history and glaucoma progression: the effect of body mass index, tobacco and alcohol consumption on the rates of structural change in patients with glaucoma, Br J Ophthalmol. 2024;108:1694-1700.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.
Mitch Ibach, OD, FAAO, details the importance of identifying the best candidates and practicing comanagement for refractive surgery.
Rachelle Lin, OD, MS, FAAO, on collaborating more effectively on neovascular retinal cases
Mark Bullimore, MCOptom, PhD, details the importance of preparing optometric students for myopic patient care in a Collaborative Care Symposium (CCS) 2025 presentation.
Peter Hersh, MD, stated that the key takeaway from a handful of presentations he gave at CCS 2025 is that successfully treating patients with keratoconus is identifying the disease early.
Steven Greenstein, MD, one of the cochairs of the Collaborative Care Symposium gave some insight into the upcoming conference and what attendees can expect.
Susana Marcos, PhD, discusses the implications her research presents for the role optical coherence tomography (OCT) could play in presbyopia and myopia accommodation efforts.
Susana Marcos, PhD, outlines a presentation she gave at ARVO 2025 on a unique utilization of optical coherence tomography.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
© 2025 MJH Life Sciences

All rights reserved.